The FDA stated its intent to modernize regulatory processes to maintain leadership.
1 report, 1 independent
Updated Sep 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA stated its intent to modernize regulatory processes to maintain leadership.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- The FDA and European Medicines Agency discussed sharing the global regulatory leadership mantle.
- Administration actions, including FDA appointments, are promoting Bitcoin and digital assets.
- Executive branch pressure influences the FDA to implement strong regulatory crackdowns.
- The FDA is accused of failing to enforce safety regulations and operating under current rules without in-person oversight.
- Michael Davis takes a permanent leadership role at the FDA's Center for Drug Evaluation and Research following senior selections announced by the Department of Health & Human Services.